Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Current Vascular Pharmacology|July 16, 2009
Future challenges for microsomal transport protein inhibitorsAnthony S Wierzbicki, Tim Hardman, William T PrinceFrontiers in Pharmacology|December 19, 2019
European Federation for Exploratory Medicines Development Lyon Conference 2019: The Changing Landscape of Early Medicines Development-Be PreparedTim Hardman, Henri Caplain, Sylvie Rottey, et al.F1000Research|November 17, 2022
Analysis of the safety and immunogenicity profile of an azoximer bromide polymer-adjuvanted subunit influenza vaccineRonald Kompier, Pieter Neels, Walter Beyer, et al.Frontiers in Pharmacology|May 10, 2019
The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion ForumKerstin Breithaupt-Grögler, Tim Hardman, Jan de Hoon, et al.Therapeutic Innovation & Regulatory Science|February 4, 2021
How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion ForumJens Rengelshausen, Kerstin Breithaupt-Groegler, Frank Donath, et al.Drugs in Context|April 8, 2021
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical studySergey V Efimov, Natallia V Matsiyeuskaya, Olga V Boytsova, et al.Allergy|July 1, 2022
Relationship between inflammatory status and microbial composition in severe asthma and during exacerbationSarah Diver, Koirobi Haldar, Pamela Jane McDowell, et al.Thorax|July 25, 2015
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)Liam G Heaney, Ratko Djukanovic, Ashley Woodcock, et al.Pageof 1